



Pharmaceuticals Limited

**Registered & Corporate Office :**

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,

Opp. SBI Executive Enclave, Banjara Hills,

Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 06<sup>th</sup> September, 2024

To  
The Manager,  
Corporate Filings Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001.

The Manager,  
Listing Compliance Department,  
National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**Security Code: 532815**

**Symbol: SMSPHARMA**

Dear Sir/Madam,

**Sub: Business Responsibility and Sustainability Report for the financial year 2023-24.**

Pursuant to Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Business Responsibility and Sustainability Report (BRSR) of the Company for the financial year 2023-24. The BRSR also forms part of the Integrated Annual Report for the Financial Year 2023-24.

Please take the above intimation on your records.

Thanking you  
Yours faithfully

**For SMS Pharmaceuticals Limited**

**Thirumalesh Tumma  
Company Secretary and Compliance Officer**

Encl: as above

# BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT (BRSR) – 2023-24

## SECTION A: GENERAL DISCLOSURES

### I. Details of the listed entity

1. Corporate Identity Number (CIN) of the Listed Entity	:	L24239TG1987PLC008066
2. Name of the Listed Entity	:	SMS Pharmaceuticals Limited
3. Year of incorporation :	:	14 <sup>th</sup> December, 1987
4. Registered office address	:	Plot. No. 72, H.No: 8-2-334/3&4, Road No: 5, Opp. SBI Executive Enclave, Banjara Hills, Hyderabad – 5000034, Telangana, India
5. Corporate address	:	Plot. No. 72, H.No: 8-2-334/3&4, Road No: 5, Opp. SBI Executive Enclave, Banjara Hills, Hyderabad – 5000034, Telangana, India
6. E-mail	:	<a href="mailto:cs@smspharma.com">cs@smspharma.com</a>
7. Telephone	:	+91-40-35359999
8. Website	:	<a href="http://www.smspharma.com">www.smspharma.com</a>
9. Financial year for which reporting is being done	:	01 <sup>st</sup> April, 2023 to 31 <sup>st</sup> March, 2024
10. Name of the Stock Exchange(s) where shares are listed	:	BSE Limited (BSE), National Stock Exchange of India Limited (NSE)
11. Paid-up Capital	:	Rs.846.52 lakhs
12. Name and contact details telephone, email address) of the person who may be contacted in case of any queries on the BRSR report	:	Mr. Thirumalesh Tumma, Company Secretary and Compliance Officer, Tele: +91-40-35359999, Email: <a href="mailto:Complianceofficer@smspharma.com">Complianceofficer@smspharma.com</a>
13. Reporting boundary - Are the disclosures under this Report made on a standalone basis or on a consolidated basis.	:	The disclosure under BRSR is on Standalone basis unless otherwise stated.

### II. Products/services

#### 14. Details of business activities (accounting for 90% of the turnover):

S. No.	Description of Main Activity	Description of Business Activity	% of Turnover of the entity
1	Manufacturing	Manufacture of Active Pharmaceutical Ingredients (APIs)	99.38

#### 15. Products/Services sold by the entity (accounting for 90% of the entity's Turnover):

S. No.	Product/Service	NIC Code	% of total Turnover Contributed
1	Manufacture of Active pharma ingredients, intermediates, custom pharmaceutical services and nutraceuticals	21001	100

### III. Operations

#### 16. Number of locations where plants and/or operations/offices of the entity are situated:

Location	Number of Plants	Number of offices	Total
National	3*	1	4
International	0	0	0

\*The plants include the Company's manufacturing locations and R&D centers.

## 17. Markets served by the entity:

## a. Number of locations

Location.	Number
National (No. of States)	18
International (No. of Countries)	42

## b. What is the contribution of exports as a percentage of the total turnover of the entity?

43%

## c. A brief on types of customers

Our customers include various pharmaceutical and nutraceutical companies across the globe.

## IV. Employees

## 18. Details as at the end of Financial Year:

## a. Employees and workers (including differently abled):

S. No.	Particulars	Total (A)	Male		Female	
			No. (B)	% (B / A)	No. (C)	% (C / A)
<b>EMPLOYEES</b>						
1.	Permanent (D)	1027	973	94.74	54	5.26
2.	Other than Permanent (E)	0	0	0	0	0.00
3.	<b>Total employees (D + E)</b>	<b>1027</b>	<b>973</b>	<b>94.74</b>	<b>54</b>	<b>5.26</b>
<b>WORKERS</b>						
4.	Permanent (F)	170	170	100.00	0	0
5.	Other than Permanent (G)	558	522	93.55	36	6.45
6.	<b>Total workers (F + G)</b>	<b>728</b>	<b>692</b>	<b>95.05</b>	<b>36</b>	<b>4.95</b>

## b. Differently abled Employees and workers:

S. No.	Particulars	Total (A)	Male		Female	
			No. (B)	% (B / A)	No. (C)	% (C / A)
<b>DIFFERENTLY ABLED EMPLOYEES</b>						
1.	Permanent (D)	0	0	0	0	0
2.	Other than Permanent (E)	0	0	0	0	0
3.	<b>Total differently abled employees (D + E)</b>					
<b>DIFFERENTLY ABLED WORKERS</b>						
4.	Permanent (F)	0	0	0	0	0
5.	Other than Permanent (G)	0	0	0	0	0
6.	<b>Total differently abled workers (F + G)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

## 19. Participation/ Inclusion/representation of Women

	Total (A)	No. and percentage of Females	
		No. (B)	% (B / A)
Board of Directors	6	1	16.67
Key Management Personnel	4	0	0

20. Turnover rate for permanent employees and workers

(Disclose trends for the past 3 years)

Particulars	Turnover rate in current FY 2023-24			Turnover rate in previous FY 2022-23			Turnover rate in the FY prior to previous FY 2021-22		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	22.99	25.24	48.23	23.3	23.4	46.7	25.5	16.67	42.17
Permanent Workers	26.75	0	26.75	1.42	0	1.42	1.46	0	1.46

V. Holding, subsidiary and Associate Companies (including Joint Ventures)

21. (a) Names of holding / subsidiary / associate companies / joint ventures

S. No.	Name of the holding/ subsidiary/ associate companies/ joint ventures (A)	Indicate whether holding/Subsidiary/ Associate/ Joint Venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
1	VKT Pharma Private Limited	Associate	36.55	No
2	CHEMO SMS ENTERPRISES SL (55% held by Chemo 45% held by SMS)	Joint Venture	45.00	No

VI. CSR Details

22. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes  
(ii) Turnover (in Rs.) 7,09,26,33,556/-  
(iii) Net worth (in Rs.) 570,48,78,058/-

VII. Transparency and Disclosures Compliances

23. Complaints/Grievance on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business

Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/No)  (If yes, then provide web-link for grievance redress policy)*	FY 2023-24			FY 2022-23		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Communities	Y	-	-	-	-	-	-
Investors (other than shareholders)	Y	-	-	-	-	-	-
Shareholders	Y	-	-	-	1	-	-
Employees and workers	Y	-	-	-	-	-	-
Customers	Y	-	-	-	-	-	-
Value Chain Partners	Y	-	-	-	-	-	-
Other (please specify)	Y	-	-	-	-	-	-

\* Various policies of the Company for redressing the grievances of its stakeholders are available at <https://smspharma.com/company-announcements/downloads/>. In addition there are internal policies placed on intranet of the Company.

## 24. Overview of the entity's material responsible business conduct issues

Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along with its financial implications, as per the following format:

S. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
1	ESG compliance	Risk and Opportunity	ESG reporting leads to identifying and managing risks, improving operations, and making better decisions. Reduce cost, emissions, discharges and improve efficiency.	The Company is always forefront in promoting and advocating Sustainability practices & standards for better environment	Positive: likely to impact financials in creating new opportunities in new markets and reduce cost.
2	Regulatory compliance	Risk	The company has customers in India and abroad, it needs to comply with laws & regulations that govern those jurisdictions. Compliance cost have increased over the years with substantiality practices given high importance by governments as well by the industry it directly and indirectly results in cost of raw material and increase in production costs	To comply with various laws and legislations Company ensures periodical audits are conducted and address all gaps and shortcomings in time bound manner.	Negative: Increase in cost of compliance in meeting various regulatory and reporting requirements across various jurisdictions in India and abroad.
3	Changing global political and economic conditions	Risk	Geo political uncertainties can affect the supply chain and increases the risk of doing business. Economic uncertainties and changes can have effect on your companies' financials and orders.	We constantly monitor various conflicts and wars across the globe, significant political and regulatory changes including policy changes affecting the industry. We are taking measures to mitigate the risks.	Negative: Geopolitical events like wars, internal conflict, changes in governments and policies can have effect the way we do our business in distribution and client deliveries and possibility in increase in costs
4	Supply chain sustainability	Risk	Supply chain risks occur in the process of purchasing or sourcing products or resources becomes unreliable or scarce. It becomes crucial to have a stable supply chain for sustainable business	The company has taken measures for improvement in the sourcing of key raw materials and sourcing from domestic market and efforts are made to reduce dependence on imports.	Negative: Disruption in supply of raw materials on time will impact on operations as well of supply of output material.
5	Environment risk	Risk	The Policy of the Company to do business in sustainable way and reduce the its impact on environment by strictly following environment laws and conserving resources. Company. Climatic and environment changes can impact the business.	Our motto, "Nurture the nature in which we exist," serves as the impetus for our constant vigilance to ensure that our operations less negative impact on environment	Negative: Compliance of Environmental laws and regulations can increase in cost of compliance and non-compliance can have long lasting environmental damage and financial loss.
6	Product and quality risk	Risk	Use of quality and standard raw materials will help in producing quality and safe products. Failure to comply with GMP (Good Manufacturing Practices) can result in regulatory fines and actions.	Audits are conducted by the Quality Assurance department to ensure that our high-quality requirements are met.	Negative: any deviation in product quality impact GMP Standards and regularity action and loose the reputation and financial and operational damage.

## SECTION B: MANAGEMENT AND PROCESS DISCLOSURES

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC Principles and Core Elements.

Disclosure Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
<b>Policy and management processes</b>									
1. a. Whether your entity's policy/policies cover each principle and its core elements of the NGRBCs. (Yes/No)	Y	Y	Y	Y	Y	Y	Y	Y	Y
b. Has the policy been approved by the Board? (Yes/No)	The policies have been approved by the Chairman and Managing Director and certain policies are approved by the Board								
c. Web Link of the Policies, if available	Many of the policies are available on the website of the Company <a href="https://smspharma.com/company-announcements/downloads/">https://smspharma.com/company-announcements/downloads/</a> and the policies which are internal to the Company are available on the Intranet of the Company								
2. Whether the entity has translated the policy into procedures. (Yes / No)	Y	Y	Y	Y	Y	Y	Y	Y	Y
3. Do the enlisted policies extend to your value chain partners? (Yes/No)	Y	Y	Y	Y	Y	Y	Y	Y	Y
4. Name of the national and international codes/ certifications/labels/ standards (e.g., Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustee) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle.	P 2 = Y P3: The company has Environmental Management System Accreditation ISO 14001. P6: The company has Occupational Health and Safety Accreditation ISO 45001								
5. Specific commitments, goals and targets set by the entity with defined timelines if any.	Have plans to recover the water as condensate from atmosphere through while using Air handling Units and expected water condensate per day will be 20KL per day								
6. Performance of the entity against the specific commitments, goals and targets along with reasons in case the same are not met.	The performance against specific commitments, goals and targets are provided in the respective capitals of the integrated annual report, wherever applicable.								
<b>Governance, leadership, and oversight</b>									
7. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements (listed entity has flexibility regarding the placement of this disclosure)	At SMS Pharma, we strive hard to translate Environmental, Social and Governance (ESG) principles into tangible actions. To create a meaningful impact on both the environment and society, we adhere to global sustainability standards and implement targeted initiatives to reduce our carbon footprint, conserve resources and foster social inclusivity.								
8. Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy (ies)	Name: Ramesh Babu Potluri Designation: Chairman and Managing Director DIN: 00166381								
9. Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability related issues? (Yes / No). If yes, provide details.	No								

10. Details of Review of NGRBCs by the Company:

Subject for Review	Indicate whether review was undertaken by Director / Committee of the Board/ Any other Committee									Frequency (Annually/ Half yearly/ Quarterly/ Any other – please specify)								
	P1	P2	P3	P4	P5	P6	P7	P8	P9	P1	P2	P3	P4	P5	P6	P7	P8	P9
	Performance against above policies and follow up action	The policies of the Company are reviewed periodically / on a need basis by department heads									Periodically/need based basis							
Compliance with statutory requirements of relevance to the principles, and, rectification of any non-compliances	Status of compliance with all applicable statutory requirements is reviewed by the Board on a quarterly basis.									Ongoing basis								

	P1	P2	P3	P4	P5	P6	P7	P8	P9
11. Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No). If yes, provide name of the agency.									
12. If answer to question (1) above is "No" i.e., not all Principles are covered by a policy, reasons to be stated:									

Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
The entity does not consider the principles material to its business (Yes/No)	-	-	-	-	-	-	-	-	-
The entity is not at a stage where it is in a position to formulate and implement the policies on specified principles (Yes/No)	-	-	-	-	-	-	-	-	-
The entity does not have the financial or/human and technical resources available for the task (Yes/No)	-	-	-	-	-	-	-	-	-
It is planned to be done in the next financial year (Yes/No)	-	-	-	-	-	-	-	-	-
Any other reason (please specify)	-	-	-	-	-	-	-	-	-

## SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE

This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key processes and decisions. The information sought is categorized as "Essential" and "Leadership." While the essential indicators are expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily disclosed by entities which aspire to progress to a higher level in their quest to be socially, environmentally, and ethically responsible.

### PRINCIPLE 1 Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable.

#### Essential Indicators

##### 1. Percentage coverage by training and awareness programmes on any of the principles during the financial year:

Segment	Total number of training and awareness programmes held	Topics / principles covered under the training and its impact	% age of persons in respective category covered by the awareness programmes
Board of Directors and Key Managerial Personnel	2	Familiarisation programs for the Board of Directors/ KMPs of the Company are done periodically. Presentations given to Board of Directors and KMP regarding the updates on Companies Act, SEBI Regulations. And, few directors attended various programs conducted by various bodies the programmes include business and industry updates, risk management, important regulatory changes and compliances of various statutory requirements, updating on various Codes/Policies of the Company, environmental, social and governance parameters, legal cases, etc.	100
Employees other than BoD and KMPs and workers	176	Employees basis their role undergoes various training programs throughout the year. This includes technical trainings, functional SOP trainings, Safety trainings, On the Job trainings, Health, Safety and Environmental trainings	100

2. **Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format.**

(Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed one entity's website):

Monetary					
	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Amount (In INR)	Brief of the Case	Has an appeal been preferred? (Yes/No)
Penalty/ Fine	-	-	-	-	-
Settlement	-	-	-	-	-
Compounding fee	-	-	-	-	-

Monetary					
	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Amount (In INR)	Brief of the Case	Has an appeal been preferred? (Yes/No)
Penalty/ Fine	-	-	-	-	-
Settlement	-	-	-	-	-
Compounding fee	-	-	-	-	-

Non-Monetary					
	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Brief of the Case	Has an appeal been preferred? (Yes/No)	
Imprisonment	-	-	-	-	
Punishment	-	-	-	-	

3. **Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases were monetary or non-monetary action has been appealed.**

Case Details	Name of the regulatory/ enforcement agencies/ judicial institutions
NA	NA

4. **Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available provide a web-link to the policy.**

No Company does not have an independent anti-bribery policy but Our employees and those representing us, including agents and intermediaries, shall not, directly, or indirectly, offer or receive any illegal or improper payments or comparable benefits that are intended or perceived to obtain undue favors for the conduct of our business. The Company has zero tolerance approach towards corruption and bribery.

5. **Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:**

	FY 2023-24	FY 2022-23
Directors	-	-
KMPs	-	-
Employees	-	-
Workers	-	-



## 6. Details of complaints with regard to conflict of interest:

	FY 2023-24		FY 2022-23	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of the Directors	-		-	
Number of complaints received in relation to issues of Conflict of Interest of the KMPs	-		-	

## 7. Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.

Not Applicable

## Leadership Indicators

## 1. Awareness programmes conducted for value chain partners on any of the principles during the financial year:

Total Number of awareness programmes held	Topics / principles covered under the training	%age of value chain partners covered (By value of Business done with such partners) under the awareness programmes
0	0	0

## 2. Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? (Yes/No) If yes, provide details of the same.

Yes, the Company's Code of Conduct expects all its Personnel (Members of the Board) to refrain from engaging in any activity or having a personal interest that presents a conflict of interest. <https://smspharma.com/wp-content/uploads/2024/06/Code-of-business-conduct-and-ethics-for-Directors-Sr-Mgt-Personnel-New.pdf>

## PRINCIPLE 2 Businesses should provide goods and services in a manner that is sustainable and safe

## Essential Indicators

## 1. Percentage of R&amp;D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&amp;D and capex investments made by the entity, respectively.

	FY 2023-24	FY 2022-23	Details of improvements in environmental and social impacts
R&D	0	0	Reduce the number of process steps to reduce the carbon footprint and to reduce the production process life cycle
Capex	57	97	

## 2. a. Does the entity have procedures in place for sustainable sourcing? (Yes/No) b. If yes, what percentage of inputs were sourced sustainably?

No

## 3. Describe the processes in place to safely reclaim your products for reusing, recycling, and disposing at the end of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.

Waste management practices become an integrated approach of waste reduction and recycling in order to enhance sustainable development. Common management practices in SMS Pharmaceuticals Ltd are Effluent segregation, collection, Treatment & Hazardous waste segregation collection, storage and safely disposed the hazardous/solid waste to the authorized TSDF/co-processor.

## 4. Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No). If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, provide steps taken to address the same.

Not Applicable

### Leadership Indicators

- Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing industry) or for its services (for service industry)? If yes, provide details in the following format?

NO

- If there are any significant social or environmental concerns and/or risks arising from production or disposal of your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or through any other means, briefly describe the same along-with action taken to mitigate the same

We have not conducted LCA for any of our products

- Percentage of recycled or reused input material to total material (by value) used in Products (for manufacturing industry) or providing services (for service industry).

We do not recycle or reuse input material

- of the products and packaging reclaimed at end of life of products, amount (in metric tons) reused, recycled, and safely disposed, as per the following format:

We do not reclaim products for reusing, recycling, and disposing them at the end of their life.

- Reclaimed products and their packaging materials (as percentage of products sold) for each product category

Not Applicable

### PRINCIPLE 3 Businesses should respect and promote the well-being of all employees, including those in their value chains

#### Essential Indicators

- Details of measures for the well-being of employees:

Category	% of employees covered by										
	Total (A)	Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care Facilities	
		Number (B)	% (B/A)	Number (C)	% (C/A)	Number (D)	% (D/A)	Number (E)	% (E/A)	Number (F)	% (F/A)
<b>Permanent employees</b>											
Male	973	290	29.80	973	100	0	0	0	0	0	0
Female	54	17	31.48	54	100	54	100	0	0	0	0
<b>Total</b>	<b>1027</b>	<b>307</b>	<b>29.89</b>	<b>1027</b>	<b>100</b>	<b>54</b>	<b>100</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Other than Permanent employees</b>											
Male	0	0	0	0	0	0	0	0	0	0	0
Female	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

- Details of measures for the well-being of workers:

Category	% of workers covered by										
	Total (A)	Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care Facilities	
		Number (B)	% (B/A)	Number (C)	% (C/A)	Number (D)	% (D/A)	Number (E)	% (E/A)	Number (F)	% (F/A)
<b>Permanent workers</b>											
Male	170	138	81.18	170	100	0	0	NA	NA	0	0
Female	0	0	0	0	0	0	0	NA	NA	0	0
<b>Total</b>	<b>170</b>	<b>138</b>	<b>81.18</b>	<b>170</b>	<b>100</b>	<b>0</b>	<b>0</b>	<b>NA</b>	<b>NA</b>	<b>0</b>	<b>0</b>
<b>Other than Permanent workers</b>											
Male	522	522	100	522	100	NA	NA	NA	NA	NA	NA
Female	36	36	100	36	100	36	100	NA	NA	NA	NA
<b>Total</b>	<b>558</b>	<b>558</b>	<b>100</b>	<b>558</b>	<b>100</b>	<b>36</b>	<b>100</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>

## 2. Details of retirement benefits, for Current FY and Previous Financial Year.

Benefits	FY 2023-24			FY 2022-23		
	No. of employees covered as a% of total employees	No. of workers covered as a% of total workers	Deducted and deposited with the authority (Y/N/N.A.)	No. of employees covered as a% of total employees	No. of workers covered as a% Of total workers	Deducted and deposited with the authority (Y/N/N.A.)
PF	100.00%	100.00%	NA	100.00%	100.00%	NA
Gratuity	100.00%	100.00%	NA	100.00%	100.00%	NA
ESI	39.07%	97.63	NA	33.75%	97.63%	NA

## 3. Accessibility of workplacesw

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard.

For differently abled employees, the infrastructure facilities across the offices and manufacturing and R&D facilities adhere to accessibility standards wherever it is required.

## 4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy.

The Company does not have policy in place, but the Company believes in equal opportunity for all its employees, wherein the Company is committed to providing an inclusive work culture and an environment free from any discrimination. SMS pharma values and welcomes diversity and does not treat anybody differently based on their race, sex, religion/beliefs, disability, marital or civil partnership status, age, sexual orientation, gender identity, gender expression, caring responsibilities, or any other class of person protected by laws in the country.

## 5 Return to work and Retention rates of permanent employees and workers that took parental leave.

Gender	Permanent employees		Permanent workers	
	Return to work rate	Retention rate	Return to work rate	Retention rate
Male	0	0	0	0
Female	1	100%	0	0
<b>Total</b>	<b>1</b>	<b>100%</b>	<b>0</b>	<b>0</b>

## 6. Is there a mechanism available to receive and redress grievances for the following categories of employees and worker? If yes, give details of the mechanism in brief.

	Yes/Nob (If yes, then give details of the mechanism in brief)
1 Permanent Workers	The Company has always believed in open and transparent communication. Employees are encouraged to share their concerns with their business heads, HR or the members of the senior management as part of the Whistleblower Policy, the Company provides a grievance redressal mechanism and encourages its employees and workers to bring to attention any instances of unethical behavior, incidents, frauds or violation. The Company has a policy on prevention, prohibition, and redressal of sexual harassment of women at the workplace and has an Internal Complaints Committee (ICC) in compliance with the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The Company's policy on the same is placed on the Company's website.
2 Other than Permanent Workers	Yes, the non-permanent employees and workers communicate their grievances through their respective supervisors. The grievances are further communicated to the Company for necessary action and resolution of the grievances.
3 Permanent Employees	A Grievance Redressal Mechanism has been constituted to hear and redress individual grievances.  The Company has formulated Whistle Blower Policy for redressing grievances. The Policy can be accessed from <a href="https://smspharma.com/wp-content/uploads/2022/08/Whistel-Blower-Protection-Policy.pdf">https://smspharma.com/wp-content/uploads/2022/08/Whistel-Blower-Protection-Policy.pdf</a>

		Yes/No (If yes, then give details of the mechanism in brief)
4	Other than Permanent Employees	A Grievance Redressal Mechanism has been constituted to hear and redress individual grievances.  The Company has formulated Whistle Blower Policy for redressing grievances. The Policy can be accessed from <a href="https://smspharma.com/wp-content/uploads/2022/08/Whistel-Blower-Protection-Policy.pdf">https://smspharma.com/wp-content/uploads/2022/08/Whistel-Blower-Protection-Policy.pdf</a>

**7. Membership of employees and worker in association(s) or Unions recognized by the listed entity:**

The Company does not have any employee associations. The Company, however, recognizes the right to freedom of association.

**8. Details of training given to employees and workers:**

Category	FY 2023-24					FY 2022-23				
	Total (A)	On Health and safety measures		On Skill upgradation		Total (D)	On Health and safety measures		On Skill upgradation	
		No. (B)	% (B/A)	No.(C)	% (C/A)		No. (E)	% (E/D)	No. (F)	% (F/D)
<b>Employees</b>										
Male	973	942	96.81	246	25.28	907	620	68.36	470	51.82
Female	54	44	81.48	35	64.81	47	35	74.47	23	48.94
<b>Total</b>	<b>1027</b>	<b>986</b>	<b>96.01</b>	<b>281</b>	<b>27.36</b>	<b>954</b>	<b>655</b>	<b>68.66</b>	<b>493</b>	<b>51.68</b>
<b>Workers</b>										
Male	170	170	100	170	100	141	141	100	141	100
Female	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>170</b>	<b>170</b>	<b>100</b>	<b>170</b>	<b>100</b>	<b>141</b>	<b>141</b>	<b>100</b>	<b>141</b>	<b>100</b>

**9. Details of performance and career development reviews of employees and Workers**

Category	FY 2023-24			FY 2022-23		
	Total (A)	No.(B)	% (B / A)	Total(C)	No. (D)	% (B / A)
<b>Employees</b>						
Male	973	0	0	907	881	97.13
Female	54	0	0	47	35	74.47
<b>Total</b>	<b>1027</b>	<b>0</b>	<b>0</b>	<b>954</b>	<b>916</b>	<b>96.02</b>
<b>Workers</b>						
Male	170	0	0	141	141	100
Female	0	0	0	0	0	0
<b>Total</b>	<b>170</b>	<b>0</b>	<b>0</b>	<b>141</b>	<b>141</b>	<b>100</b>

**10. Health and safety management system:**

- a. **Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If yes, the coverage such system?**

Yes, all manufacturing locations under the entity have an Occupational Health and Safety management system in place, in accordance with the guidelines provided by OHSAS IS 14489 & ISO45001 :2018 standards and the legal requirements such as Factories Act, Indian Boilers Act, Environment Protection Act, among others.

- b. **What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?**

The Company undertakes periodic internal and external audits to ensure the compliance of Occupational Health and Safety management system within the manufacturing operation. The EHS trainings, audits and inspections are carried out as per the guidelines of OHSAS IS 14489 & ISO45001 :2018 standard. The Company's Process Safety Management system facilitates the implementation of best safety practices. Further, it enables the identification of work-related hazards through design checklists.

**c. Whether you have processes for workers to report the work-related hazards and to remove themselves from such risks. (Y/N)**

Yes, The Company has well-established Standard Operating Procedures (SOP) for employees and workers to identify and report on work-related hazards and the subsequent steps to mitigate them. In addition, the Company trains all its employees and workers with occupational health and safety. The training cover aspects to identify work-related hazards, analyze the risks associated with it and take subsequent steps to mitigate them. During the safety and emergency evacuation drills, employees are trained in dealing with emergency equipment such as fire hydrant, firefighting system, leak and spill control procedures, safety alarms among others. The practical trainings equip the employees with right procedure of reporting work-related hazards and the steps to remove themselves from such situations

**d. Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? (Yes/ No)**

Yes, the Company provides non-occupational medical and healthcare services to its employees and workers. Further, the Company ensures the provision of medical insurance to all its employees and workers. In addition, personnel are being trained to respond appropriately to medical emergencies on-site

**11. Details of safety related incidents, in the following format:**

Parameter	Category*	FY 2023-24	FY 2022-23
Lost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)	Employees	0	0
	Workers	0	0
Total recordable work-related injuries	Employees	0	0
	Workers	0	0
No. of fatalities	Employees	0	0
	Workers	0	0
High consequence work-related injury or ill-health (excluding fatalities)	Employees	0	0
	Workers	0	0

**12. Describe the measures taken by the entity to ensure a safe and healthy work place.**

We emphasize strongly on the health, safety, and well-being of our people. We continuously strive to create a work environment that is free from any occupational hazards, whether it is at plants, Corporate Office or Research center. We have implemented strong health and safety systems at all our plants. These systems are guided and driven by our established policies and procedures. Periodic assessments are conducted to evaluate the effectiveness of the systems implemented and appropriate measures are taken to further improve our H&S performance continually

**13. Number of Complaints on the following made by employees and workers:**

	FY 2023-24			FY 2022-23		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Working Conditions	0	0	Nil	0	0	Y
Health & Safety	0	0	Nil	0	0	-

**14. Assessments for the year:**

	% of your plants and offices that were assessed (By entity or statutory authorities or third parties)
Health and safety practices	100%
Working Conditions	100%

**15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions.**

All safety related accidents are being investigated and learnings from investigation reports are shared across organization for deployment of corrective actions to stop recurrence of such incidents. Effectiveness of Corrective actions deployment being checked during safety Audits.

**Leadership Indicators**

**1. Does the entity extend any life insurance or any compensatory package in the event of death of (A) Employees (Y/N) (B) Workers (Y/N).**

No (the company has accidental death insurance PA)

**2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners.**

The Company collects the proofs of deposits of statutory dues like payment challans etc. from the service value chain partners before releasing their bills regularly and ensures that the statutory dues have been deducted and deposited by the value chain partners with the relevant statutory authorities. The Company ensures that statutory dues as applicable to the transactions are deducted and deposited in accordance with extant regulations.

**3. Provide the number of employees / workers having suffered high consequence work related injury / ill-health / fatalities (as reported in Q11 of Essential Indicators above), who have been are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment:**

	Total no. of affected employees/ workers		No. of employees/workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment	
	FY 2023 -24	FY 2022-23	FY 2023-24	FY 2022-23
Employees	0	0	0	0
Workers	0	0	0	0

**4. Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/ No)**

The Company periodically provides skill-upgradation training programs to all its employees during their employment to enable the employees to pursue employment post-retirement or termination, based on the acquired skillset.

**5. Details on assessment of value chain partners:**

The value chain partners are expected to adhere to the principles of Health and safety practices, working conditions as per extant regulations. However, no independent assessment is carried out.

**6. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from assessments of health and safety practices and working conditions of value chain partners.**

There were no significant risks/concerns identified during the supplier assessments.

**PRINCIPLE 4: Businesses should respect the interests of and be responsive to all its stakeholders****Essential Indicators****1. Describe the processes for identifying key stakeholder groups of the entity.**

The Company identified key stakeholder groups based on those groups who are impacted as well those who have a major influence on the business decisions. The key internal and external stakeholder groups identified by the Company as part of the engagement mechanism are Investors and shareholder, regulators, Governments, suppliers/vendors/, Value Chain Partners, Non-Governmental Organizations (NGO), Community, Customer B2B, Employees, Senior leadership, and the society. We consider individuals, groups, institutions, or entities that contribute to shaping our business that add value or constitute a core part of the business value chain as key stakeholders.

**2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.**

<b>Stakeholder Group</b>	<b>Whether identified as Vulnerable &amp; Marginalized Group (Yes/No)</b>	<b>Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other</b>	<b>Frequency of engagement (Annually/ Half yearly/ Quarterly/ others – please specify)</b>	<b>Purpose and scope of engagement including key topics and concerns raised during such engagement</b>
Investor/ Shareholder	No	Email, newspaper advertisement, website, Annual General Meetings, intimation to stock exchanges, annual/ quarterly financials and investor meetings/ conferences	Frequent and need based	To stay abreast of developments in the Company and its subsidiary companies
Regulator & Government	No	one-on-one meetings, conferences	Need Based	Our engagement with official authorities is multi-fold. With regulatory authorities, our engagement is aimed at discharging responsibilities and furthering our core business of product development, launch, manufacturing, etc. in keeping with the latest and highest standards of compliance. With policy-makers, our engagement aims to understand and discuss matters pertaining to the industry
Supplier/ vendor/ third party manufacturer	No	Multiple channels – physical and digital	Frequent and need based	Helps to increase reach and enhance business
NGO /Community	No	Multiple channels – physical and digital	Frequent and need based	To promote social welfare activities for inclusive growth, fair and equitable development and wellbeing of society through our business functioning and Support socially projects, Community Development
Customer B2B	No	Multiple channels – physical and digital	Frequent	We engage with our customers to ensure regular supply of the products, keep them informed about new products, participate in the bids/ tenders and maximize the outreach of our products. Helps to increase reach and enhance business

Stakeholder Group	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly/ others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
Employees	No	Direct & other communication mechanisms	Quarterly	To create a thriving, safe and inclusive workplace for its employees and providing merit-based opportunities for professional development and growth. Aim to provide employees a safe, inclusive workplace. Our ongoing effort is to maintain two-way engagement with colleagues globally including those in corporate offices, manufacturing locations and in the field.

### Leadership Indicators

1. **Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.**

The Company ensure transparent communication and access to relevant information about its decisions that impact relevant stakeholders, keeping in mind the need to protect confidential competitive plans and information. The Board of Directors are updated on various developments arising out of such engagement and they provide their guidance /inputs on such matters, the identified material issues were presented to the highest governing member and the Board for their feedback and guidance.

2. **Whether stakeholder consultation is used to support the identification and management of environmental, and social topics (Yes / No). If so, provide details of instances as to how the inputs received from stakeholders on these topics were incorporated into policies and activities of the entity.**

The Company believes that our products help in promoting and creating a healthy world and help in combating disease and mitigate suffering of millions of people across the world. In addition, the Company has engaged a ESG consultant and expert in this field, which helps to better understand expectations of stakeholders and benchmark against best practices.

3. **Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ marginalized stakeholder groups.**

The Company through its CSR policies have taken up various initiatives and activities for the benefit of different segments of the society, with focus on the marginalized, poor, needy, deprived, under-privileged and differently abled persons, for further details <https://smspharma.com/wp-content/uploads/2022/08/corporate-social-responsibility-policy.pdf>



## PRINCIPLE 5 Businesses should respect and promote human rights

### Essential Indicators

1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:

Category	FY 2023-24			FY 2022-23		
	Total (A)	No. employees workers covered (B)	% (B/A)	Total (C)	No. employees workers covered (D)	% (D/C)
<b>Employees</b>						
Permanent	1027	1027	100	954	954	100
Other than permanent	0	0		0	0	0
<b>Total Employees</b>	<b>1027</b>	<b>1027</b>	<b>100</b>	<b>954</b>	<b>954</b>	<b>100</b>
<b>Workers</b>						
Permanent	170	170	100	141	141	100
Other than permanent	558	558	100	484	484	100
<b>Total Workers</b>	<b>728</b>	<b>728</b>	<b>100</b>	<b>625</b>	<b>625</b>	<b>100</b>

2. Details of minimum wages paid to employees and workers, in the following format:

Category	FY 2023-24					FY 2022-23				
	Total (A)	Equal to Minimum Wage		More than Minimum Wages		Total (D)	Equal to minimum wages		More than Minimum Wages	
		No. (B)	% (B/A)	No.(C)	% (C/A)		No. (E)	% (E/D)	No. (F)	% (F/D)
<b>Employees</b>										
Permanent	1027	100	9.74	927	90.26	954	235	24.63	719	75.37
Male	973	95	9.76	878	90.24	907	225	24.81	682	75.19
Female	54	5	9.26	49	90.74	47	10	21.28	37	78.72
Other than Permanent	0	0	0	0	0	0	0	0	0	0
Male	0	0	0	0	0	0	0	0	0	0
Female	0	0	0	0	0	0	0	0	0	0
<b>Workers</b>										
<b>Permanent</b>	170	148	87.06	22	12.94	141	0	0	141	100
Male	170	148	87.06	22	12.94	141	0	0	141	100
Female	-	-	-	-	-	0	0	0	0	0
<b>Other than Permanent</b>	558	454	81.36	104	18.64	484	404	83.47	80.00	16.53
Male	522	418	80.08	104	19.92	450	370	82.22	80.00	17.78
Female	36	36	100.00	-	-	34	34	100	0	0.0

3. Details of remuneration/salary/wages, in the following format:

	Male		Female	
	Number	Median remuneration/ salary/ wages of respective category	Number	Median remuneration salary/wages of respective category
Board of Directors (BoD)	5	5,90,000	1	4,80,000
Key Managerial Personnel	2	19,12,625	0	0
Employees other than BoD and KMP	969	3,77,500	54	3,77,500
Workers	170	1,81,500	0	0

**4. Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)**

Yes. The Managing Director of the Company oversees the human resources function in the Company. In addition, the HR Head along with the other Sr. executives are responsible for addressing any human rights issues caused or contributed by the business.

**5. Describe the internal mechanisms in place to redress grievances related to human rights issues.**

We see to conduct our business in a manner that respects the human rights and dignity of people. SMS Pharmaceuticals Ltd. does not tolerate retaliation. We consider acts of retaliation to be misconduct. The Company regards respect for human rights as one of its fundamental and core values and strives to support, protect and promote human rights to ensure that fair and ethical business and employment practices are followed, we have a Grievance redressal mechanism for its employees in the form of Whistle blower policy and a formal grievance mechanism is available to all employees, to report or raise their concerns confidentially and anonymously, without fear of any retaliation.

Refer to <https://smspharma.com/wp-content/uploads/2024/06/Code-of-business-conduct-and-ethics-for-Directors-Sr-Mgt-Personnel-New.pdf>

**6. Number of Complaints on the following made by employees and workers:**

	FY 2023-24			FY 2022-23		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Sexual Harassment	0	0	NA	0	0	NA
Discrimination at workplace	0	0	NA	0	0	NA
Child Labour	0	0	NA	0	0	NA
Forced Labour/Involuntary Labour	0	0	NA	0	0	NA
Wages	0	0	NA	0	0	NA
Other human rights related issues	0	0	NA	0	0	NA

**7. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.**

Refer to: <https://smspharma.com/wp-content/uploads/2024/06/Code-of-business-conduct-and-ethics-for-Directors-Sr-Mgt-Personnel-New.pdf>

**8. Do human rights requirements form part of your business agreements and contracts? (Yes/No)**

YES

**9. Assessments for the year:**

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Child labour	100%
Forced/involuntary labour	100%
Sexual harassment	100%
Discrimination at workplace	100%
Wages	100%
Others – please specify	0%

**10. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 9 above.**

Not Applicable

**Leadership Indicators****1. Details of a business process being modified / introduced as a result of addressing human rights grievances/complaints.**

There were no such grievances/complaints in the Company.

**2. Details of the scope and coverage of any Human rights due-diligence conducted.**

No such third party due diligence was conducted.

**3. Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?.**

The premises/ offices of the Company, including the registered offices and plants have ramps or have elevators and relevant infrastructure for differently abled individuals where ever it is required based on the job location

**4. Details on assessment of value chain partners:**

	<b>% of value chain partners (by value of business done with such partners) that were assessed</b>
Sexual Harassment	The Company expects its value chain partners to adhere to the same values, principles and business ethics as upheld by the Group in all their dealings. No specific assessment in respect of value chain partners has been carried out other than certain elements covered in annual review of processes and controls.
Discrimination at workplace	
Child Labour	
Forced Labour/Involuntary Labour	
Wages	
Others – please specify	

**5. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 4 above.**

Not Applicable

**PRINCIPLE 6: Businesses should respect and make efforts to protect and restore the environment****Essential Indicators****1. Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format:**

<b>Parameter</b>	<b>FY 2023-24</b>	<b>FY 2022-23</b>
Total electricity consumption (A)	158920	107058
Total fuel consumption (B)	388395.59	340390.46
Energy consumption through other sources (C)	0	0
<b>Total energy consumption (A+B+C)</b>	<b>547315.59</b>	<b>447448.46</b>
Energy intensity per rupee of turnover (Total energy consumption/ turnover in rupees)	0.000076685	0.000069775
Energy intensity (optional) – the relevant metric may be selected by the entity		

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

No

**2. Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any.**

No, the Company does not have any sites/facilities identified as designated consumer under the Performance Achieve and Trade (PAT) Scheme of the Government of India.

3. Provide details of the following disclosures related to water, in the following format:

Parameter	FY 2023-24	FY 2022-23
Water withdrawal by source (in kiloliters)		
(i) Surface water	Nil	Nil
(ii) Groundwater	87626	40503
(iii) Third party water	3183	3145
(iv) Seawater / desalinated water	Nil	Nil
(v) Others	75064	13423.65
<b>Total volume of water withdrawal (in kiloliters) (i + ii + iii + iv + v)</b>	<b>165873</b>	<b>57071.65</b>
Total volume of water consumption (in kiloliters)	165873	57071.65
Water intensity per rupee of turnover (Water consumed / turnover)	0.0000232405	0.000010705
Water intensity (optional) – the relevant metric may be selected by the entity		

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency. – NO

4. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.

At SMS Pharma, we view water through the interconnected lenses of effective usage and conservation. We have to improve water conservation by recycling / condensate water and streamlining processes.

Installed 200 KLD RO Plant for waste water treatment. Currently we are getting 138KLD of water after treatment, which is enable us to conserve our water consumption from 300KLD to 162 KLD. Total Saving Ground Water 138KL/Day.

Enhanced the condensate recovery through controls in the steam condensate System and increased the condensate collection from 65 % to 75%, there by resulted in savings of makeup water by 120 KL/day, contributes 60% with respect to total feed water consumption/day. By improving the steam condensate recovery, not only reducing water consumption also benefited with coal savings by 45 Tones/Year.

Apart from water conservation through utilities we are reusing 16000 Lts of water in stage -2 of Ibuprofen process which is being used in Ibuprofen Stage-5 for every batch of Ibuprofen. The total quantity of water reused by this recycling process tuned to 535KL per month

The potential for environmental pollution prevention is one of the guiding factors in developing the route of synthesis and also converting by products to useful raw materials for the process.

SMS has developed a commercial process to get Neopentyl glycol (from waste generated in the process as residue), which is one of the key raw materials in Ibuprofen process. By developing the Neopentyl glycol synthesis from waste stream, not only commercial benefit but also environmental protection is also addressed.

5. Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:

Parameter	Please specify unit	FY 2023-24	FY 2022-23
NOx	Tons	5.08	42.65
SOx	Tons	6.97	61.71
Particulate matter (PM)	Tons	8.24	83.57
Persistent organic pollutants (POP)	Tons	NA	NA
Volatile organic compounds (VOC)	PPM	10.78	20.96
Hazardous air pollutants (HAP)	Tons	NA	NA
Others– please specify	Tons	NA	NA

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

YES, it was carried out SV ENVIRO LABS & CONSULTANTS, Environmental Engineers & Consultants in Pollution Control at unit-7

6. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format:

Parameter	Please specify unit	FY 2023-24	FY 2022-23
Total Scope 1 emissions (Break-up of the GHG into CO <sub>2</sub> , CH <sub>4</sub> , N <sub>2</sub> O, HFCs, PFCs, SF <sub>6</sub> , NF <sub>3</sub> , if available)	Metric tonnes of CO <sub>2</sub> equivalent	37382.48	32757.7
Total Scope 2 emissions (Break-up of the GHG into CO <sub>2</sub> , CH <sub>4</sub> , N <sub>2</sub> O, HFCs, PFCs, SF <sub>6</sub> , NF <sub>3</sub> , if available)	Metric tonnes of CO <sub>2</sub> equivalent	42378.97	28551.17
Total Scope 1 and Scope 2 emissions per rupee of turnover	Metric tonnes of CO <sub>2</sub> equivalent	0.0000059377	0.00000994235
Total Scope 1 and Scope 2 emission intensity (optional) – the relevant metric may be selected by the entity			

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

NO

7. Does the entity have any project related to reducing Green House Gas emission? If yes, then provide details.

NO

8. Provide details related to waste management by the entity, in the following format:

Parameter	FY 2023-24	FY 2022-23
<b>Total Waste generated (in metric tonnes)</b>		
Plastic waste (A)	21.74	9.66
E-waste (B)	0.23	0.02
Bio-medical waste (C)	0.51	0.46
Construction and demolition waste (D)	0.09	0.13
Battery waste (E)	Nil	3.73
Radioactive waste (F)	Nil	Nil
Other Hazardous waste. Please specify, if any. (G)	1667.88	301.47
Other Non-hazardous waste generated (H). Please specify, if any. (Break-up by composition i.e., by materials relevant to the sector)	40.94	24.48
<b>Total (A+B + C + D + E + F + G+ H)</b>	<b>1731.40</b>	<b>339.95</b>
<b>For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)</b>		
<b>Category of waste</b>		
(i) Recycled	75064	13423.65
(ii) Re-used	67.60	31.18
(iii) Other recovery operations	Nil	Nil
<b>Total</b>	<b>75131.60</b>	<b>13454.83</b>
<b>For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)</b>		
<b>Category of waste</b>		
(i) Incineration	35.15	83.22
(ii) Landfilling	1616.18	227.68
(iii) Other disposal operations	Nil	Nil
<b>Total</b>	<b>1651.33</b>	<b>310.9</b>

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency

NO

9. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.

Waste management practices become an integrated approach of waste reduction and recycling in order to enhance sustainable development. Common management practices in SMS Pharmaceuticals Ltd are Effluent segregation, collection, Treatment & Hazardous waste segregation collection, storage and safely disposed the hazardous/solid waste to the authorized TSDF/co-processor.

Hazardous waste generated from process, filter press, Stripper, ATFD and distillation columns in Solvent recovery block safely stored in dedicated hazardous waste storage shed and timely (Not more than 90 days) disposed to APEMC authorized TSDF/co-processor/cement industries with online manifest and GPS tracking.

10. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required, please specify details in the following format:

S. No.	Location of operations /offices	Type of operations	Whether the conditions of environmental approval / clearance are being complied with? (Y/N) If no, the reasons thereof and corrective action taken, if any.
1	Kandivalasa Village, Vizianagaram (D)	Bulk Drug Manufacturing (API)	Yes

11. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:

No environmental impact assessments were undertaken in FY 2023-24

12. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:

All the manufacturing operations and R&D centers under the entity are in compliance with the applicable environmental laws/ regulations and guidelines as per the national and state level mandates

### Leadership Indicators

1. Provide break-up of the total energy consumed (in Joules or multiples) from renewable and non-renewable sources, in the following format:

Parameter	FY 2023-24	FY 2022-23
<b>From renewable sources</b>		
Total electricity consumption (A)	-	-
Total fuel consumption (B)	-	-
Energy consumption through other sources (C)	-	-
<b>Total energy consumed from renewable sources (A+B+C)</b>	-	-
<b>From non-renewable sources:</b>		
total electricity consumption (D)	158920	107058
Total fuel consumption (E)	388395.59	5293.461
Energy consumption through other sources (F)	-	-
<b>Total energy consumed from non-renewable sources (D+E+F)</b>	<b>547315.59</b>	<b>112351.55</b>

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

NO

## 2 Provide the following details related to water discharged:

Parameter	FY 2023-24	FY 2022-23
Water discharge by destination and level of treatment (in kilolitres)		
(i) To Surface water		
- No treatment	Nil	Nil
- With treatment – please specify level of treatment	Nil	Nil
(ii) To Ground water	-	-
- No treatment	Nil	Nil
- With treatment – please specify level of treatment	Nil	Nil
(iii) To Seawater	-	-
- No treatment	Nil	Nil
- With treatment – please specify level of treatment	6512.29 KL	3584.98 KL
(iv) Sent to third-parties	-	-
- No treatment	Nil	Nil
- With treatment – please specify level of treatment	Nil	Nil
(v) Others	-	-
- No treatment	Nil	Nil
- With treatment – please specify level of treatment	Nil	Nil
<b>Total water discharged (in kilolitres)</b>	<b>6512.29 KL</b>	<b>3584.98 KL</b>

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency - NO

## 3. Water withdrawal, consumption, and discharge in areas of water stress (in kiloliters):

Not Applicable. Our facilities are not located in areas of water stress.

## 4. Please provide details of total Scope 3 emissions & its intensity, in the following format.

Parameter	Unit	FY 2023-24	FY 2022-23
<b>Total Scope 3 emissions</b> (Break-up of the GHG into CO <sub>2</sub> , CH <sub>4</sub> , N <sub>2</sub> O, HFCs, PFCs, SF <sub>6</sub> , NF <sub>3</sub> , if available)	Metric tonnes of CO <sub>2</sub> equivalent	200.61	31.87
<b>Total Scope 3 emissions per rupee of turnover</b>		0.000000028	0.0000000061
<b>Total Scope 3 emission intensity</b> (optional) – the relevant metric may be selected by the entity			

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

NO

## 5 With respect to the ecologically sensitive areas reported at Question 10 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and remediation activities.

At SMS pharmaceuticals Ltd, we have 2 solvent recovery blocks SRB-I & SRB-II total 16 We provided fire safety arrangements and spark arrestors and FLP electrical fittings. We have installed VOC absorption media columns in SRB-I & SRB-II with VOC Monitor. And all the vents connected to VOC absorption media column. And the column placed at height of 06 meters above from the roof top. Generated Residues and spent mixed solvents from the process collected and safely storage until disposal to APEMC authorized TSDF/co-processor/cement industries.

### Initiatives Undertaken to Improve Resources Reduce Emissions:

We have taken few initiatives to improve reduce process emissions & fugitive emissions for the process emissions control we have installed double stage scrubbers with online pH meters connected to APPCB website and monitor 24/7. And control fugitive emission we have installed double stage vent condensers in every production block. And installed vent condensers to solvent storage tanks and Online VOC monitor installed.

6 If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the same as well as outcome of such initiatives, as per the following format:

Sr. No	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along-with summary)	Outcome of the initiative
1	<p><b>Waste water treatment:</b> We are at SMS Pharmaceuticals Ltd effluents segregated in to two streams High-TDS Effluent and Low-TDS Effluent.</p> <p><b>High-TDS Effluent:</b> High-TDS Effluent is collected from production blocks and neutralize effluent pH 7 to 7.5 than effluent transferred to primary treatment system consist flash mixer, flocculation, and clarifier with chemical dosing's here we separate suspended solids from effluent. Sludge settles down to clarifier bottom and sludge transfer to sludge collection tank and then transfer to filter press for removing water from the sludge then sludge collected in bags and stored in dedicated hazardous waste storage shed for further disposal to authorized co-processor/cement industries. Overflow water from clarifier collected in storage tank then transfer to MEE (Multiple effects Evaporator) feed. Here we collect condensate water in condensate storage tank and transfer this to biological treatment system for further treatment. Concentrate from MEE transfer to ATFD and generated hazardous waste (MEE Salt) collected in to bags and stored in dedicated hazardous waste storage shed for further disposal to authorized TSDF/co-processor/cement industries.</p> <p><b>Low-TDS Effluent:</b> Low-TDS Effluent collected from Domestic effluent, RO Plant rejects, cooling towers blowdowns, MEE Condensate, and boiler blowdowns in to low-TDS effluent collection tank after that transferred to oil &amp; grease chamber for remove oil &amp;grease from the effluent then transferred to Equalization tank-I &amp; II for aeration. Then transferred to biological treatment plant for further treatment outlet of biological treatment will be transferred to RO Plant for further treatment. RO Plant outlet will be transferred to ETP Outlet collection tank. Collected recycled water reused for cooling towers makeup &amp; Boiler feed. From last financial year 2023-24 we have recycled and re used 32,542 KL and in another plant 1,530 KL recycled and reused.</p>	Bulk Drug Manufacturing (API)	From last Financial Year 2023-24 we have recycled and re used 34072 KL.
2	<p><b>Energy Conservation Measures taken:</b> Energy Conservation continues to receive priority within the Company. The continuous monitoring of the energy Consumptions across the Company's locations, has resulted in improvement in maintenance systems and reduction in Distribution losses.</p> <p><b>Steps taken by the Company for utilizing the alternate sources of energy:</b> 01. Facility created to purchase power through open access during the power holiday time to avoid the running of diesel generator sets and saving of HSD. Participating in the Open access bidding to get the power in the cheaper price as compared to the discom prices as per available slots to reduce the power cost. /Year: Rs.35Lakhs/Year.</p>		1,64,664 units per year saving. & 300 Units per day per each chiller.



Sr. No	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along-with summary)	Outcome of the initiative
	<p><b>Energy Conservation Measures taken:</b></p> <p>01. Installed LED Lights instead of CFL lights in both areas like intermediate and pharm in all blocks and QC for power saving 1656 Units/Month.</p> <p>02. Implemented numerous energy conservation activities in utilities and block equipment through performance assessments, automation of equipment, standard procurement of energy efficient equipment ie, installation of energy efficient motors &amp; Pump sets.</p> <p>03. VFDs are provided for Screw Chillers at resulting in a daily energy savings of 300 units per day @ Each Chiller.</p> <p>04. Replacement of existing +5degC water-cooled reciprocating type chillers with new energy efficient water-cooled screw type refrigeration systems installed. This resulted in saving of 80,000Units/Year.</p> <p>05. Replaced manually operated valves of utilities with automated control valves to reduce the utility Consumption at the Production Blocks.</p> <p>06. Installed online tube cleaning systems (ECO MAX) for Chilling plants condensers tube cleaning purpose and improve the Condenser Heat Transfer Area and Reduce the discharge pressures and Maintain the Standard of KW/TR :0.75.</p> <p>07. Installed Common header for compressed air circuit for optimum utilization of air compressor So Saving in Power Units/Day :30Units/Day.</p> <p>08. Installed Steam Condensate Recovery System to achieve increased efficiency of the boilers &amp; reduce the fuel consumption.</p> <p>09. Installed Steam Condensate Recovery Pumps (Pressure Powered Pump) Steam Condensate Water pumping purpose, so there are centrifugal pumps are replaced with Pressure Powered Pump, so there are power Saving in Units/day: 150Units/day.</p> <p>10. Installed Steam Operated Pumping traps used for Solvent Recovery Systems so there are reduce in the process cycle time and steam &amp; power consumption.</p>		
3	<p><b>Water Conservation Measures taken:</b></p> <p>At SMS Pharma, we view water through the interconnected lenses of effective usage and conservation. We have endeavored to improve water conservation by recycling / condensate water and streamlining processes.</p> <p>Installed 200 KLD RO Plant for waste water treatment. Currently we are getting 138KLD of water after treatment, which is enable us to conserve our water consumption from 300KLD to 162 KLD. Total Saving Ground Water 138KL/Day.</p> <p>Further SMS has been planned to recover the water as condensate from atmosphere through while using Air handling Units and expected water condensate per day will be 20KL per day</p>		Total savings of 278 KL per day

Sr. No	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along-with summary)	Outcome of the initiative
	<p>Enhanced the condensate recovery through controls in the steam condensate System and increased the condensate collection from 65 % to 75%, there by resulted in savings of makeup water by 120 KL/ day, contributes 60% with respect to total feed water consumption/day. By improving the steam condensate recovery, not only reducing water consumption also benefited with coal savings by 45 Tones/Year.</p> <p>Apart from water conservation through utilities we are reusing 16000 Lts of water in stage -2 of Ibuprofen process which is being used in Ibuprofen Stage-5 for every batch of Ibuprofen. The total quantity of water reused by this recycling process tuned to 535 KL per month</p> <p>The potential for environmental pollution prevention is one of the guiding factors in developing the route of synthesis and converting by products to useful raw materials for the process.</p> <p>SMS has developed a commercial process to get Neopentyl glycol (from waste generated in the process as residue), which is one of the key raw materials in Ibuprofen process. By developing the Neopentyl glycol synthesis from waste stream, not only commercial benefit but also environmental protection is also addressed</p>		

**7 Does the entity have a business continuity and disaster management plan? Give details in 100 words/ web link.**

SMS Pharmaceuticals Limited has prepared Emergency preparedness plan and to check effectiveness of the plan by means of conducting mock drills in regular intervals. These rehearsals are effective in familiarizing personnel with their functions in emergency, will help to evaluate the available equipment, its effectiveness adequacy. In the year 2023-24 training given to our employees (638) on emergency preparedness plan.

**8 Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard.**

Not applicable

**9 Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts.**

In the reporting period, the Company did not evaluate any of its value chain partners.

**PRINCIPLE 7 Businesses when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent**

**Essential Indicators**

**1. a. Number of affiliations with trade and industry chambers/ associations.**

4

**b. List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the entity is a member of/ affiliated to.**

Sr. No	Name of the trade and industry chambers/ associations	Reach of trade and industry chambers/ associations (State/National)
1	Confederation of Indian Industry	National
2	Bulk Drug Manufacturers Association	State
3	FTCCI	State
4	Pharmexcil	National

**2. Provide details of corrective action taken or underway on any issues related to anti- competitive conduct by the entity, based on adverse orders from regulatory authorities.**

For the reporting year, there were no cases issued against the Company.

**Leadership Indicators**

**1. Details of public policy positions advocated by the entity:**

SMS is member of various trade and industry chambers, associations, councils. We proactively contribute to the discussions and resolutions within the scope of these forum. The Company works closely with various trade and industry associations. SMS maintains regular engagement with the Government agencies and regulators and stands committed to providing timely and accurate information, suggestions and recommendations, feedback on draft policies.

**PRINCIPLE 8 Businesses should promote inclusive growth and equitable development**

**1. Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.**

In the reporting year, the Company did not undertake any Social Impact Assessment

**2. Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity, in the following format:**

In the reporting year, the Company did not undertake any ongoing Rehabilitation and Resettlement (R&R) project.

**3. Describe the mechanisms to receive and redress grievances of the community.**

The communities can raise their grievances as per the mechanism provided in our Code of Conduct available on our website of the Company

**4. Percentage of input material (inputs to total inputs by value) sourced from suppliers:**

Parameter	FY 2023-24	FY 2022-23
Directly sourced from MSMEs/ small producers	6	5
Sourced directly from within the district and neighboring districts	39	20

**Leadership Indicators**

**1. Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments (Reference: Question 1 of Essential Indicators above):**

In FY 2023-24, no Social Impact Assessments conducted

**2. Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies:**

S. No.	State	Aspirational District	Amount spent Lakhs (In INR)
1	Andhra Pradesh, Vizianagaram	Ongoing Projects Construction of Community hall in Kumili Village, Pusapatirega Mandal Vizianagaram Distirict Andhra Pradesh for the usage of village people and nearby villages people for agricultural reforms, social and cultural gatherings. This village is located surrounding area of Company's Unit VII facility.	80.00
2	Andhra Pradesh, Vizianagaram	Continued financial support for Campus Challenge, Konada Junction (On NH- 16), Kotha Kopperla (PO), Singavaram (SO), Vizianagaram Dist-535213. Campus Challenge is works for disadvantaged children in Coastal and Tribal Andhra Pradesh. Their main goal is to create ability and facilitate the process of empowerment of the person with disabilities.	5.40

S. No.	State	Aspirational District	Amount spent Lakhs (In INR)
3	Telangana, Hyderabad	Continuing Support to poor people crippled with heart, lung and vascular diseases, through Dr. Alla Gopala Krishna Gokhale, Sahrudaya Health, Medical and Educational Trust	10.00
4	Telangana, Hyderabad	Community CC TV Project- Installation of Cameras under Dundigal Police Station, Cyberabad Commissionerate for the safety of women, children in the surrounding areas of educational institutions and industries.	9.79

**3. (a) Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalized /vulnerable groups? (Yes/No)**

Small scale industries form a crucial part of Company's business partner base. We encourage to procure raw materials and other material for operations from small-scale units and other sections of the society closely located in and around our plant location to help them grow and develop a viable eco systems for overall development of all sections of the society. Majority of daily services are executed through engaging neighborhood communities. We continuously strive to build local alternate vendors for other materials

**(b) From which marginalized /vulnerable groups do you procure?**

Not identifiable

**(c) What percentage of total procurement (by value) does it constitute?**

NA

**4. Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current financial year), based on traditional knowledge:**

The Company does not derive any benefits from intellectual properties owned or acquired based on traditional knowledge

**5. Details of corrective actions taken or underway, based on any adverse order in intellectual property related disputes wherein usage of traditional knowledge is involved.**

Not applicable.

**6. Details of beneficiaries of CSR Projects:**

S. No.	CSR Project	No. of persons benefitted from CSR Projects	% of beneficiaries from vulnerable and marginalized groups
1	Ongoing Projects Construction of Community hall in Kumili Village, Pusapatirega Mandal Vizianagaram Distirict Andhra Pradesh for the usage of village people and nearby villages people for agricultural reforms, social and cultural gatherings. This village is located surrounding area of Company's Unit VII facility.	1500	80%
2	Continued financial support for Campus Challenge, Konada Junction (On NH- 16), Kotha Kopperla (PO), Singavaram (SO), Vizianagaram Dist-535213. Campus Challenge is works for disadvantaged children in Coastal and Tribal Andhra Pradesh. Their main goal is to create ability and facilitate the process of empowerment of the person with disabilities.	15	100%
3	Continuing Support to poor people crippled with heart, lung and vascular diseases, through Dr. Alla Gopala Krishna Gokhale, Sahrudaya Health, Medical and Educational Trust	5	100%
4	Community CC TV Project- Installation of Cameras under Dundigal Police Station, Cyberabad Commissionerate for the safety of women, children in the surrounding areas of educational institutions and industries.	3000	70%

**PRINCIPLE 9 Businesses should engage with and provide value to their consumers in a responsible manner****Essential Indicators****1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback.**

Communication received through Mail and same escalated concern team to solve the issue and proper CAPA

**2. Turnover of products and/ services as a percentage of turnover from all products /service that carry information about:**

	As a percentage to total turnover
Environmental and social parameters relevant to the product	-
Safe and responsible usage	15
Recycling and/or safe disposal	10

**3. Number of consumer complaints in respect of the following:**

	FY 2023-24		Remarks	FY 2022-23		Remarks
Data privacy	-	-	NA			NA
Advertising	-	-	NA	-	-	NA
Cyber-security	-	-	NA	-	-	NA
Delivery of essential services	-	-	NA	-	-	NA
Restrictive Trade Practices	-	-	NA	-	-	NA
Unfair Trade Practices	-	-	NA	-	-	NA
Other	-	-	NA	-	-	NA
			NA	-	-	NA

**4. Details of instances of product recalls on account of safety issues:**

	Number	Reasons for recall
Voluntary recalls	0	NA
Forced recalls	0	NA

**5. Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No) If available, provide a web-link of the policy.**

No

**6. Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data \privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services.**

There are no complaints received for issues pertaining to delivery of essential services, advertising, cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products/ services For FY 2023-24

**Leadership Indicators****1. Channels / platforms where information on products and services of the entity can be accessed (Provide web link, if available).**

<https://smspharma.com/api/>

<https://smspharma.com/central-laboratory-analytical-services/>

<https://smspharma.com/crams/>

**2. Steps taken to inform and educate consumers about safe and responsible usage of products and/or services**

Product information of Safety Data Sheet and Certificate of Analysis is enclosed during Transit

3. Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.

Not applicable

4. Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/No/Not Applicable) If yes, provide details in brief. Did your entity carry out any survey regarding consumer satisfaction relating to the major products / services of the entity, significant locations of operation of the entity or the entity as a whole? (Yes/No)

No

5. Provide the following information relating to data breaches:

a. Number of instances of data breaches along-with impact - **NIL**

b. Percentage of data breaches involving personally identifiable information of customers - **NIL**